You are here:

fulvestrant (Faslodex)

Advice

in the absence of a submission from the holder of the marketing authorisation:

fulvestrant (Faslodex®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: fulvestrant (Faslodex)
SMC Drug ID: 1294/17
Manufacturer: AstraZeneca UK Ltd
Indication: Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 11 December 2017

Back